Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib Induction in Locally Advanced HNSCC
NCT01732640Phase 2Terminated
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Dec 2012
- Primary completion
- Nov 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of afatinib in head and neck squamous cell carcinoma (HNSCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Primary endpoints: Maximum Tolerated Dose of Afatinib at 1 year, Objective Tumor Response Rate at 8 weeks and 1 more. Started Dec 2012; status: terminated.
02
Drugs
afatinib
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT01732640.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01732640.